ARCT vs. EOLS, PAHC, BCYC, IRON, YMAB, ANAB, PLRX, SLN, NUVB, and PRAX
Should you be buying Arcturus Therapeutics stock or one of its competitors? The main competitors of Arcturus Therapeutics include Evolus (EOLS), Phibro Animal Health (PAHC), Bicycle Therapeutics (BCYC), Disc Medicine (IRON), Y-mAbs Therapeutics (YMAB), AnaptysBio (ANAB), Pliant Therapeutics (PLRX), Silence Therapeutics (SLN), Nuvation Bio (NUVB), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical preparations" industry.
Arcturus Therapeutics (NASDAQ:ARCT) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, community ranking, dividends, media sentiment and earnings.
Arcturus Therapeutics received 86 more outperform votes than Evolus when rated by MarketBeat users. However, 71.88% of users gave Evolus an outperform vote while only 65.34% of users gave Arcturus Therapeutics an outperform vote.
94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 90.7% of Evolus shares are owned by institutional investors. 13.8% of Arcturus Therapeutics shares are owned by insiders. Comparatively, 5.4% of Evolus shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Arcturus Therapeutics currently has a consensus target price of $61.33, suggesting a potential upside of 126.66%. Evolus has a consensus target price of $20.60, suggesting a potential upside of 56.65%. Given Arcturus Therapeutics' higher probable upside, equities research analysts plainly believe Arcturus Therapeutics is more favorable than Evolus.
Arcturus Therapeutics has a net margin of -15.65% compared to Evolus' net margin of -30.52%. Evolus' return on equity of 0.00% beat Arcturus Therapeutics' return on equity.
Arcturus Therapeutics has higher earnings, but lower revenue than Evolus. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks.
Arcturus Therapeutics has a beta of 2.65, indicating that its stock price is 165% more volatile than the S&P 500. Comparatively, Evolus has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500.
In the previous week, Evolus had 9 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 10 mentions for Evolus and 1 mentions for Arcturus Therapeutics. Evolus' average media sentiment score of 0.16 beat Arcturus Therapeutics' score of -0.14 indicating that Evolus is being referred to more favorably in the news media.
Summary
Arcturus Therapeutics beats Evolus on 11 of the 17 factors compared between the two stocks.
Get Arcturus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arcturus Therapeutics Competitors List
Related Companies and Tools
